MUMBAI, India and VANCOUVER, BC, July 13, 2022 /PRNewswire/ Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven, global pharmaceutical company and SaNOtize Research and Development Corp, today announced that The Lancet Regional Health Southeast Asia (TLRHSEA) - peer reviewed, high impact journal published the successful phase 3 clinical trial results of SaNOtize's Nitric Oxide Nasal Spray (NONS) study titled: 'SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial'. https://www.thelancet.com/journals/lansea/article/PIIS2772-3682(22)00046-4/fulltext "We are excited to publish the study of the novel Nitric Oxide Nasal Spray, which positively impacts the lives of people, in The Lancet group of journals. The robust double-blind trial demonstrated significant efficacy and remarkable safety of NONS. This therapy has the potential to make a crucial contribution to COVID-19 management, with its ease of use in